of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasis (BCLM). This is the first prospective randomized phase III study globally on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback